Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) hit a new 52-week low during trading on Monday . The stock traded as low as $4.25 and last traded at $4.41, with a volume of 84882 shares. The stock had previously closed at $4.77.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on COGT. Robert W. Baird decreased their price target on Cogent Biosciences from $10.00 to $8.00 and set a "neutral" rating on the stock in a research report on Thursday, February 27th. Needham & Company LLC reaffirmed a "hold" rating on shares of Cogent Biosciences in a report on Wednesday, February 26th. Wedbush reissued a "neutral" rating and issued a $11.00 price target on shares of Cogent Biosciences in a report on Tuesday, February 25th. Scotiabank began coverage on shares of Cogent Biosciences in a report on Friday, March 7th. They issued a "sector outperform" rating and a $17.00 price target on the stock. Finally, HC Wainwright dropped their price objective on Cogent Biosciences from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $14.43.
Read Our Latest Stock Analysis on COGT
Cogent Biosciences Trading Up 6.0 %
The business's fifty day moving average price is $6.91 and its 200-day moving average price is $8.62. The company has a market capitalization of $485.00 million, a P/E ratio of -1.72 and a beta of 1.67.
Hedge Funds Weigh In On Cogent Biosciences
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Schonfeld Strategic Advisors LLC bought a new stake in Cogent Biosciences in the 4th quarter worth approximately $78,000. Hsbc Holdings PLC bought a new stake in shares of Cogent Biosciences in the 4th quarter worth approximately $81,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Cogent Biosciences in the 4th quarter valued at $88,000. E Fund Management Co. Ltd. bought a new position in shares of Cogent Biosciences during the 4th quarter valued at $89,000. Finally, Proficio Capital Partners LLC purchased a new position in Cogent Biosciences in the 4th quarter worth $93,000.
Cogent Biosciences Company Profile
(
Get Free Report)
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Featured Articles
Before you consider Cogent Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list.
While Cogent Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
